Coronary Disease Clinical Trial
Official title:
Genetic Susceptibility to Common Lipid Disorders in Mexico
Familial combined hyperlipidemia (FCHL) is an inherited disorder characterized by elevated levels of cholesterol and triglycerides; it often occurs in Mexican individuals with coronary heart disease (CHD). The purpose of this study is to identify the specific genes that predispose Mexican individuals to FCHL.
CHD is the leading cause of death in Mexico. Dyslipidemia that is characterized by high
total cholesterol, high triglycerides, and low "good" high-density lipoprotein (HDL)
cholesterol is a risk factor for developing CHD. Research has shown that the Mexican
population has an increased tendency towards dyslipidemia, but it is not known what genetic
factors contribute to this predisposition. This study will examine the genetic basis of
FCHL, which is an inherited form of dyslipidemia characterized by elevated levels of total
cholesterol and triglycerides. FCHL is a major contributing factor in CHD; 20% of
individuals with CHD under the age of 60 have FCHL. The purpose of this study is to identify
and characterize the specific DNA sequence variations that predispose Mexican individuals to
FCHL. Results of this study may aid in the development of appropriate prevention and
screening techniques.
This study will enroll individuals in Mexico who have FCHL. Participants will attend one
study visit for blood collection and DNA sampling. Family members of participants will be
contacted and asked to provide a DNA sample also. A select group of participants will return
for a second study visit for RNA sampling. Study researchers will analyze participants' DNA
and RNA samples, as well as two FCHL genes identified in previous research studies.
;
Observational Model: Family-Based, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Completed |
NCT05672862 -
International Post-PCI FFR Extended Registry
|
||
| Completed |
NCT04492423 -
VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
|
||
| Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
| Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
| Completed |
NCT00046410 -
Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting
|
N/A | |
| Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
| Completed |
NCT02784873 -
High Intensity Interval Training in UK Cardiac Rehabilitation Programmes
|
N/A | |
| Not yet recruiting |
NCT02895009 -
Hemostatic Compression Patterns After Transradial Coronary Intervention
|
N/A | |
| Completed |
NCT02948517 -
Time Restricted Feeding for Weight Loss and Cardio-protection
|
N/A | |
| Recruiting |
NCT02859480 -
Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI
|
Phase 4 | |
| Withdrawn |
NCT02418143 -
A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
|
||
| Completed |
NCT02510547 -
Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial
|
Phase 4 | |
| Completed |
NCT02382731 -
Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction
|
N/A | |
| Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
| Completed |
NCT02248415 -
Administration of Warm Blood Cardioplegia With or Without Roller Pump
|
N/A | |
| Recruiting |
NCT01207167 -
Mediators of Atherosclerosis in South Asians Living in America
|
||
| Completed |
NCT02088138 -
Functional Electrical Stimulation in Cardiac Patients
|
N/A | |
| Completed |
NCT02133807 -
Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis
|
Phase 3 | |
| Completed |
NCT02173067 -
Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective
|
N/A |